Ramos Rodrigo N, Piaggio Eliane, Romano Emanuela
Translational Immunotherapy Siric Team, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France.
Center of Cancer Immunotherapy, Institut Curie, PSL Research University, Paris, 75005, France.
Handb Exp Pharmacol. 2018;249:109-128. doi: 10.1007/164_2017_11.
Immunotherapy using checkpoint inhibitors has changed the way we treat several aggressive cancers such as melanoma, non-small cell lung and head & neck cancers, among others, with durable responses achieved in the metastatic setting. However, unfortunately, the vast majority of patients do not respond to checkpoint inhibition therapy and a minority of patients, who do respond to treatment, develop secondary resistance and experience relapse by mechanisms still inadequately understood. Emerging evidence shows that alterations in multiple signaling pathways are involved in primary and/or secondary resistance to checkpoint inhibition. In this review we discuss how selected cancer-cell autonomous cues may influence the outcome of cancer immunotherapy, particularly immune checkpoint inhibition.
使用检查点抑制剂的免疫疗法改变了我们治疗几种侵袭性癌症的方式，如黑色素瘤、非小细胞肺癌和头颈癌等，在转移性情况下实现了持久缓解。然而，不幸的是，绝大多数患者对检查点抑制疗法无反应，而少数对治疗有反应的患者会产生继发性耐药，并通过仍未完全了解的机制复发。新出现的证据表明，多种信号通路的改变与对检查点抑制的原发性和/或继发性耐药有关。在这篇综述中，我们讨论了特定的癌细胞自主信号如何可能影响癌症免疫治疗的结果，特别是免疫检查点抑制。
